🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites

RecruitingPhase 2Ages 18 Years - anyAllNational Medical Research Radiological Centre of …
NCT06856603 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Currently, the standard of care for patients with diagnosed metastatic cancer is drug therapy (chemotherapy, targeted therapy, or immunotherapy). However, the approach to oligometastatic disease (1-5 metastases) is evolving. An increasing number of de novo, persistent, and progressive oligometastatic tumors are now being treated with curative intent, with radiation therapy among the most effective treatment options, applied to metastatic sites in ablative doses. Emerging results from the SABR-COMET 3 and 5 trials, which investigate stereotactic ablative radiotherapy for patients with 1-3 and 1-5 metastatic sites, demonstrate a clear improvement in overall survival. However, patients with more than five metastases remain in a gray area. The aim of our study is to assess the safety and effectiveness of radiation treatment for patients with tumors of various localizations and 6 to 10 metas

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ECOG status 0-3 * Persistent or progressive cancer disease with 6 to 10 metastases * ≤ 5 metastases in one organ * Life expectancy \> 6 months for intracranial lesions * Inability to surgically resect all metastatic lesions * Positive tumor board decision for trial inclusion * Signed informed consent Exclusion Criteria: * ECOG status 4 * De novo metastatic disease * Radiological complete response after drug therapy * Brain metastasis only * Brain metastasis \> 3 cm, requiring neurosurgery * Size of any metastasis \> 5 cm * Previous radiation therapy for any metastatic site * Leptomeningeal, pleural, or peritoneal carcinomatosis * Spinal cord compression, requiring neurosurgery * Invasion of great vessels, skin, or GI tract * Negative tumor board decision for trial inclusion * Unsigned informed consent
💊

What it tests

  • stereotactic radiation therapy in ablative doses to each metastatic site
📍

Where

1 site
A. Tsyb Medical Radiological Research Center
Obninsk, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy